MX2022005879A - Tratamiento y prevencion de la enfermedad del dengue. - Google Patents

Tratamiento y prevencion de la enfermedad del dengue.

Info

Publication number
MX2022005879A
MX2022005879A MX2022005879A MX2022005879A MX2022005879A MX 2022005879 A MX2022005879 A MX 2022005879A MX 2022005879 A MX2022005879 A MX 2022005879A MX 2022005879 A MX2022005879 A MX 2022005879A MX 2022005879 A MX2022005879 A MX 2022005879A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
dengue
dengue disease
infected
Prior art date
Application number
MX2022005879A
Other languages
English (en)
Spanish (es)
Inventor
Johan Neyts
Suzanne Kaptein
Bart Rudolf Romanie Kesteleyn
Jean- François Bonfanti
Tim Hugo Maria Jonckers
Goethals Olivia Gabriella M
Bart Henri Theresia Stoops
Loock Marnix Van
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2022005879A publication Critical patent/MX2022005879A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022005879A 2019-11-15 2020-11-13 Tratamiento y prevencion de la enfermedad del dengue. MX2022005879A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19209593 2019-11-15
EP19213851 2019-12-05
EP20171172 2020-04-23
PCT/EP2020/082102 WO2021094563A1 (en) 2019-11-15 2020-11-13 Treatment and prevention of dengue disease

Publications (1)

Publication Number Publication Date
MX2022005879A true MX2022005879A (es) 2022-06-14

Family

ID=73288639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005879A MX2022005879A (es) 2019-11-15 2020-11-13 Tratamiento y prevencion de la enfermedad del dengue.

Country Status (14)

Country Link
US (1) US20220409583A1 (https=)
EP (1) EP4058019A1 (https=)
JP (1) JP2023502053A (https=)
KR (1) KR20220101679A (https=)
CN (1) CN114980884A (https=)
AU (1) AU2020382911A1 (https=)
BR (1) BR112022009199A2 (https=)
CA (1) CA3161338A1 (https=)
IL (1) IL292970A (https=)
MX (1) MX2022005879A (https=)
PH (1) PH12022551160A1 (https=)
TW (1) TW202132269A (https=)
UA (1) UA129409C2 (https=)
WO (1) WO2021094563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218285A1 (en) * 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Also Published As

Publication number Publication date
KR20220101679A (ko) 2022-07-19
UA129409C2 (uk) 2025-04-16
CA3161338A1 (en) 2021-05-20
EP4058019A1 (en) 2022-09-21
JP2023502053A (ja) 2023-01-20
TW202132269A (zh) 2021-09-01
US20220409583A1 (en) 2022-12-29
CN114980884A (zh) 2022-08-30
PH12022551160A1 (en) 2023-09-25
WO2021094563A1 (en) 2021-05-20
AU2020382911A1 (en) 2022-06-30
IL292970A (en) 2022-07-01
BR112022009199A2 (pt) 2022-07-26

Similar Documents

Publication Publication Date Title
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
ECSP18073264A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
CR20180493A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201800039A (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
UY36339A (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
MX2022005879A (es) Tratamiento y prevencion de la enfermedad del dengue.